Please login to the form below
venture capital
This page shows the latest venture capital news and features for those working in and with pharma, biotech and healthcare.
UK biotech funding falls 40% between 2018 and 2019
Out of that amount, £679m was raised in venture capital, £64m was raised in Initial Public Offerings (IPOs) and £596m in all other public financings. ... According to the report, global venture capital deals totalled £14.5bn in 2019, down 12%, with
Latest news
-
Merck acquires pre-clinical biotech Calporta for up to $576m
Calporta was one of eight San Diego-based biotechs created as part of a deal between venture capital firm Avalon Ventures and pharma giant GlaxoSmithKline. ... COI Pharmaceuticals is the venture-pharma entity established by Avalon to support its
-
Amgen exits neuroscience R&D to focus on growth areas
example through its collaboration with deCode Genetics, and will be “exploring potentially different models for doing that with venture capital and perhaps academic institutions as well”.
-
Biogen’s R&D chief Ehlers heads for the exit
Along with his CEO role at Limelight, Ehlers is also taking on a CSO position at venture capital firm Apple Tree.
-
Johnson pledges £200m cash injection into UK’s life sciences sector
The investment aims to help companies within the sector to raise capital – to run clinical trials, employ more industrial scientists and develop manufacturing capabilities. ... He added “this is particularly important in the coming weeks as UK-based
-
Mega-mergers dominate as buoyant markets lift biopharma
Venture capital is also fuelling biotech funding, with $3bn raised in Q2.
Merck acquires pre-clinical biotech Calporta for up to $576m
Amgen exits neuroscience R&D to focus on growth areas
Biogen’s R&D chief Ehlers heads for the exit
Johnson pledges £200m cash injection into UK’s life sciences sector
Mega-mergers dominate as buoyant markets lift biopharma
More from news
Approximately 2 fully matching, plus 106 partially matching documents found.
Latest Intelligence
-
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
of antibiotic-focused biotech SelectX Pharmaceuticals, followed by venture capital investing supporting antibiotic companies, as Chairman of the board of antibiotic-focused Macrolide Pharmaceuticals, and now as CEO of the AMR
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Larger pharmaceutical companies also have relied on hybrid venture capital firms, corporate venture capital arms and/or incubators for sourcing R&D innovation. ... For example, GlaxoSmithKline, one of the early movers in this space, founded the venture
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
The cell therapy, gene therapy and tissue engineering sector raised $2.9bn in venture capital in 2018 – twice the 2017 amount.
-
Switzerland: a life sciences hub
Approximately 40% of the capital of European life sciences companies is traded on the SIX Swiss exchange – a reflection of Switzerland’s historical ties with the sector. ... The main struggle for these start-ups is access to sufficient venture capital
-
AI: the smart money is on the smart thinking
This is coupled with venture capital (VC) being increasingly attracted to the sector. ... Therefore, it is highly likely that Big Pharma and venture capital will continue to target AI-focused companies in the coming months and years.
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
Sourcing R&D innovation: why pharma companies need to evolve their business models
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Switzerland: a life sciences hub
AI: the smart money is on the smart thinking
More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.
Latest appointments
-
Henry Skinner has been appointed as the first CEO of the AMR Action Fund
Skinner joins the AMR Action Fund with extensive biomedical and investment funding experience, having spent decades in the biomedical research, venture and the pharmaceutical industries. ... Most recently, he served as the senior vice president of
-
New hires at EMA, Gilead and BeiGene
Most recently, Grant was chief executive officer of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease.
-
AstraZeneca taps internal candidate to become UK president
Prior to joining AZ, Keith-Roach worked in technology venture capital and strategy consulting for a period of ten years.
-
Recruiters PIR International appoint four new executives
He has a track record of delivering global retained search assignments at executive and board level, partnering with venture capital and private equity funded growth stage businesses to drive patient centric
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
He has held roles for Hovione Capital, a life science focused venture capital company, and has served on several life science company boards.
Henry Skinner has been appointed as the first CEO of the AMR Action Fund
New hires at EMA, Gilead and BeiGene
AstraZeneca taps internal candidate to become UK president
Recruiters PIR International appoint four new executives
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest from PMHub
-
Are you ready for the digital health revolution?
We interview industry leading experts, CEOs, venture capitalists, patient and customer engagement experts and more, to uncover the changing landscape.
-
Newcells Biotech secures over £5m for 3D tissue models
The funding comes from two existing backers. Mercia has invested from its Northern Venture Capital Trust (VCT) and Enterprise Investment Scheme (EIS) funds and the North East Venture Fund (NEVF), which
-
University spin-out fund makes half a million pound first investments
There are plans for the fund to be the nucleus of a larger venture capital fund, which is in the early stages of development.
-
Random42 Attending Jefferies 2018 London Healthcare Conference
This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
-
Random42 appoints Bill Collis as Chairman
He has vast experience in venture capital and private equity funding, intellectual property licensing, mergers and acquisitions and accessing international markets.
More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
- Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in
No results were found
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
